Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
24 Aprile 2024 - 1:00PM
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical
stage biotechnology company developing innovative therapeutics for
fibro-inflammatory diseases with high unmet need, today announced
the company will report its first quarter 2024 financial results
and provide a business update on May 9, 2024, at 7:00 am Eastern
Time.
Investors who would like to discuss the financial results or
business update after the earnings release has been issued are
invited to contact the company at IR@chemomab.com.
About Chemomab Therapeutics Ltd.Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
that neutralizes CCL24 activity. In clinical and preclinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported positive results from three clinical trials of CM-101
in patients, including a Phase 2a liver fibrosis trial in NASH
patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with topline data
expected midyear 2024. Chemomab’s CM-101 program for the treatment
of systemic sclerosis is Phase 2-ready with an open U.S. IND. For
more information about Chemomab, visit chemomab.com.
Contacts:
Media and Investors:Barbara LindheimConsulting
Vice President, Investor & Public Relations, Strategic
CommunicationsPhone: +1
917-355-9234barbara.lindheim@chemomab.comIR@chemomab.com
Grafico Azioni Chemomab Therapeutics (NASDAQ:CMMB)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Chemomab Therapeutics (NASDAQ:CMMB)
Storico
Da Giu 2023 a Giu 2024